Skip to content

Effectiveness of Varmam therapy and Karuppu vishnu chakkara maathirai(Siddha medicine)in Epilepsy

A Comparative clinical trial on efficacy of Varmam therapy and Karuppu vishnu chakkara maathirai (internally) in the management of Kakkaivalippu (Epilepsy)

Status
Recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/07/020131
Enrollment
30
Registered
2019-07-10
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G00-G99- Diseases of the nervous system

Interventions

Intervention1: Karuppu vishnu chakkaram and varmam therapy: varmam is a special therapy and karuppu vishnuchakkaram is an internal medicine Intervention2: Karuppu vishnu chakkaram maathirai Varmam the

Sponsors

Ayothidoss Pandithar Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Blinking and upward rolling of eyes Stare blankly Repeated jerky movements of face neck arms Brief muscle jerk singly or in series involving single or multiple muscles Loss of awareness Loss of consciousness Disturbances in movement and sensation

Exclusion criteria

Exclusion criteria: Patients with uncontrolled Hypertension and diabetes mellitus Secondary epilepsy due to severe brain injury brain tumour stroke congenital brain malformations Status epilepticus Hysterical seizures Pregnancy and lactation

Design outcomes

Primary

MeasureTime frame
Outcome will be based on decrease in seizure episode and durationTimepoint: After 45 days from starting date outcome will be measured

Secondary

MeasureTime frame
Study the siddha basic principles To know the incidence of epilepsy in different age groupTimepoint: 12 months

Countries

India

Contacts

Public ContactDr Vrindha K V

National Institute of Siddha

njmuthu@hotmail.com9444206843

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026